Baylor College of Medicine Launches Immunotherapy Study for Brain Cancer

Brain Cancer


Baylor College of Medicine has secured Investigational New Drug regulatory clearance to perform a Phase I clinical trial in newly-diagnosed adult patients with glioblastoma (GBM), a highly lethal form of brain cancer with a five-year survival rate of less than 10% in most gage groups.

Pending institutional approval, the glioblastoma study will be conducted at MD Anderson Center at Cooper in Camden, NJ and overseen by Dr. Joseph Georges, a neurosurgery resident at Cooper University Health Care and the Philadelphia College of Osteopathic Medicine.

The Technology

The vaccine technology was developed by Baylor researchers and works by “tricking” the immune system into treating cancer as it would a viral infection through the reprogramming of powerful immune cells known as dendritic cells.  The inventor, Dr. William Decker, notes “if you can convince the immune system that the cancer is a viral infection you can generate a more powerful anti-cancer immune response than ordinarily possible through regular vaccination techniques.   Dr. Georges noted declared “I saw the power of this vaccine approach in the laboratory when conducting PhD studies, and I believe it has the...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee